In postmortem studies, we discovered vascular transcriptional changes in AD, identified their predicted astrocytic molecular partners, prioritized pericytic SMAD3 upregulation and astrocytic VEGFA downregulation in AD for follow-up, validated these perturbations using orthogonal approaches and replicated in external brain snRNAseq datasets. Here, SMAD3 is linked to Alzheimer disease.